Salvage Therapy Including Foscarnet and Ibalizumab for Multidrug-Resistant Human Immunodeficiency Virus Type 2 Infection.

Antoine Bachelard,Quentin Le Hingrat, Valentine-Marie Ferré, Minh Lê,Gilles Peytavin, Florence Damond, Charlotte Charpentier, Guillemette Fremont Goudot, Jeanne Goupil de Bouille,Sylvie Lariven,Pierre Delobel,Yazdan Yazdanpanah,Diane Descamps,Sophie Matheron,Jade Ghosn, ANRS CO VIH- cohort study group

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America（2024）

引用 0|浏览1

暂无评分

摘要

We evaluated Ibalizumab (IBA)-containing standardized optimized salvage regimen (with or without a 4-week foscarnet induction) in individuals harboring multidrug-resistant human immunodeficiency virus type 2 (HIV-2). Nine were included; 2 achieved virological suppression after foscarnet induction with a sustained suppression at Week 24 after IBA initiation, and an additional individual at Week 24 after Ibalizumab initiation.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要